ABACUS MEDICINE A/S financials
ABACUS MEDICINE A/S
213800834ZHT73HVF251 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €1.82B | €1.49B |
| Cost of sales | €1.62B | €1.32B |
| Gross profit | €196.9M | €171.0M |
| Administrative expenses | €98.1M | €79.9M |
| Depreciation & amortisation | €16.3M | €13.1M |
| Operating profit (EBIT) | €27.6M | €37.5M |
| Finance costs | €16.3M | €17.6M |
| Profit before tax | €12.2M | €21.5M |
| Income tax expense | €4.4M | €3.9M |
| Profit for the year | €7.8M | €17.6M |
| Total comprehensive income | €7.6M | €17.0M |
| Cash flow statement | ||
| Net cash from operating activities | €24.5M | €44.5M |
| Net cash from investing activities | -€44.5M | -€18.1M |
| Purchase of PP&E (capex) | €8.5M | €9.6M |
| Purchase of intangibles | €7.5M | €8.5M |
| Net cash from financing activities | €26.0M | -€19.7M |
| Dividends paid | €6.6M | €0 |
| Proceeds from borrowings | €37.5M | -€13.1M |
| Lease liability payments | €4.3M | €4.1M |
| Net change in cash | €6.0M | €6.7M |
| Balance sheet | ||
| Total assets | €494.7M | €357.3M |
| Non-current assets | €125.5M | €70.7M |
| Property, plant & equipment | €25.9M | €19.0M |
| Right-of-use assets | €16.9M | €6.7M |
| Intangible assets & goodwill | €74.7M | €38.1M |
| Current assets | €369.2M | €286.6M |
| Inventories | €258.3M | €229.5M |
| Trade & other receivables | €95.0M | €47.1M |
| Cash & equivalents | €16.0M | €10.0M |
| Total equity | €98.5M | €95.9M |
| Non-current liabilities | €56.3M | €6.4M |
| Long-term borrowings | €25.5M | €0 |
| Lease liabilities (non-current) | €12.5M | €3.5M |
| Current liabilities | €339.9M | €255.0M |
| Current portion of long-term borrowings | €59.8M | €47.8M |
| Lease liabilities (current) | €5.1M | €3.8M |
| Deferred tax liabilities | €3.9M | €1.5M |
| Derived metrics | ||
| Free cash flow | €16.1M | €34.9M |
| Operating margin | 1.5% | 2.5% |
| Net margin | 0.4% | 1.2% |
| Return on equity | 7.9% | 18.4% |
| Cash conversion ratio | 3.15× | 2.53× |
| Capex coverage | 2.89× | 4.64× |
| Other reported items | ||
| Adjustments For Depreciation and Amortisation Expense | €16.3M | €13.1M |
| Adjustments For Finance Costs | €16.3M | €17.6M |
| Adjustments For Finance Income | €885.0K | €1.6M |
| Adjustments For Gain Loss On Disposal of Investments In Subsidiaries Joint Ventures and Associates | €0 | €3.0K |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €28.2M | €0 |
| Current Prepayments | €8.1M | €2.6M |
| Current Provisions | €9.8M | €6.3M |
| Current Tax Liabilities Current | €2.4M | €4.3M |
| Deferred Tax Assets | €7.2M | €6.6M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€26.0K | €16.0K |
| Equity and Liabilities | €494.7M | €357.3M |
| Finance Income | €885.0K | €1.6M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | €0 | €0 |
| Income Taxes Paid Refund Classified As Operating Activities | €7.6M | €8.6M |
| Increase Decrease In Working Capital | -€4.2M | -€20.1M |
| Interest Paid Classified As Operating Activities | €16.7M | €17.8M |
| Interest Received Classified As Operating Activities | €790.0K | €266.0K |
| Investments In Subsidiaries Joint Ventures and Associates | €84.0K | €84.0K |
| Issued Capital | €519.0K | €516.0K |
| Liabilities | €396.2M | €261.4M |
| Noncurrent Provisions | €12.9M | €0 |
| Other Comprehensive Income | -€179.0K | -€646.0K |
| Other Comprehensive Income Before Tax Cash Flow Hedges | €0 | €0 |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | -€179.0K | -€646.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Before Tax | -€179.0K | -€646.0K |
| Other Current Payables | €32.0M | €22.1M |
| Other Expense By Function | €53.6M | €40.5M |
| Other Noncurrent Payables | €1.4M | €1.4M |
| Other Noncurrent Receivables | €585.0K | €235.0K |
| Other Reserves | -€3.4M | -€3.7M |
| Proceeds From Exercise of Warrants | €532.0K | €0 |
| Retained Earnings | €101.4M | €92.4M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €0 | €3.0K |
| Trade and Other Current Payables To Trade Suppliers | €222.7M | €168.1M |
Every line item above is a fact tagged in ABACUS MEDICINE A/S's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.